Future research should establish whether addition of Ki-67 immunohistochemistry to the currently used WHO definition could potentially improve the WHO Classification and further substantiate the diagnosis of WI tumors, as Ki-67 is associated with higher recurrence rates and lower DSS in FTC (37, 38). This evidence concerns the gene MKI67 and thyroid cancer, nonmedullary, 2.